The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Electrocortical changes associated with minocycline treatment in fragile X syndrome
Open accessAbstract
Minocycline normalizes synaptic connections and behavior in the knockout mouse model of fragile X syndrome (FXS). Human-targeted treatment trials with minocycline have shown benefits in behavioral measures and parent reports. Event-related potentials (ERPs) may provide a sensitive method of monitoring treatment response and changes in coordinated brain activity. Measurement of electrocortical changes due to minocycline was done in a double-blind, placebo-controlled crossover treatment trial in children with FXS. Children with FXS (Mean age 10.5 years) were randomized to minocycline or placebo treatment for 3 months then changed to the other treatment for 3 months. The minocycline dosage ranged from 25–100 mg daily, based on weight. Twelve individuals with FXS (eight male, four female) completed ERP studies using a passive auditory oddball paradigm. Current source density (CSD) and ERP analysis at baseline showed high-amplitude, long-latency components over temporal regions. After 3 months of treatment with minocycline, the temporal N1 and P2 amplitudes were significantly reduced compared with placebo. There was a significant amplitude increase of the central P2 component on minocycline. Electrocortical habituation to auditory stimuli improved with minocycline treatment. Our study demonstrated improvements of the ERP in children with FXS treated with minocycline, and the potential feasibility and sensitivity of ERPs as a cognitive biomarker in FXS treatment trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ERP habituation deficits in humans with FXS are reversed by minocycline treatment but the underlying mechanisms are not known (Schneider et al. 2013).”
From Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome (2016) · cites this paper as Schneider et al. 2013
In the citing paper
“The reduced habituation of N1 amplitude in Fmr1 KO mice is similar to observations in humans with FXS providing, for the first time, an analogous functional sensory outcome measure in mice and humans (Castren et al., 2003; Van der Molen et al., 2012; Schneider et al., 2013).”
From Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome (2016) · cites this paper as Schneider et al., 2013
In the citing paper
“Treatment with minocycline, which reduces MMP-9 activity and levels, reduces ERP habituation deficits humans with FXS (Schneider et al., 2013).”
From Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome (2016) · cites this paper as Schneider et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Spherical splines for scalp potential and current density mapping
Perrin, F., Pernier, J., Bertrand, O., & Echallier, J. F. (1989) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(89)90180-6 · Cited by 2,706
Picton, T. W., Bentin, S., Berg, P., Donchin, E., Hillyard, S. A., Johnson, R., Miller, G. A., Ritter, W., Ruchkin, D. S., Rugg, M. D., et al. (2000) · Psychophysiology · doi:10.1111/1469-8986.3720127 · Cited by 2,157
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Duncan, C. C., Barry, R. J., Connolly, J. F., Fischer, C., Michie, P. T., Näätänen, R., Polich, J., Reinvang, I., & Van Petten, C. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.07.045 · Cited by 1,191
DNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465
Näätänen, R., Kujala, T., Escera, C., Baldeweg, T., Kreegipuu, K., Carlson, S., & Ponton, C. W. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.09.020 · Cited by 447
Audiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01499.x · Cited by 289
Research works printed but not linked: 1
- Schneider A, 2012, 13th international fragile X conference
Cited by
Sorted by citations
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationBerry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270
Self-citationReinhard, S. M., Razak, K., & Ethell, I. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00280 · Cited by 219
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207
Sinclair, D., Oranje, B., Razak, K. A., Siegel, S. J., & Schmid, S. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.029 · Cited by 198
“Treatment with candidate pharmacotherapy minocycline can decrease N1 and P2 amplitudes in individuals with FXS (Schneider et al., 2013), suggesting that auditory ERP abnormalities can be used as outcome measures in drug treatment in human studies.”
Ethridge, L. E., White, S. P., Mosconi, M. W., Wang, J., Byerly, M. J., & Sweeney, J. A. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.48 · Cited by 188
Fragile X–associated tremor/ataxia syndrome
Hagerman, P. J., & Hagerman, R. J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12693 · Cited by 172
Self-citationThe Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170
Ethridge, L. E., White, S. P., Mosconi, M. W., Wang, J., Pedapati, E. V., Erickson, C. A., Byerly, M., & Sweeney, J. A. (2017) · Molecular Autism · doi:10.1186/s13229-017-0140-1 · Cited by 164
Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
Budimirovic, D. B., Berry‐Kravis, E., Erickson, C. A., Hall, S. S., Hessl, D. R., Reiss, A. L., King, M. K., Abbeduto, L., & Kaufmann, W. E. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9193-x · Cited by 159
Self-citationSidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1162-14.2014 · Cited by 155
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 157
Self-citationTranslation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome.
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.012 · Cited by 154
Sensory Processing Phenotypes in Fragile X Syndrome
Rais, M., Binder, D. K., Razak, K. A., & Ethell, I. M. (2018) · ASN NEURO · doi:10.1177/1759091418801092 · Cited by 143
Green, J., & Garg, S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12892 · Cited by 138
McDiarmid, T. A., Bernardos, A. C., & Rankin, C. H. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.028 · Cited by 119
Lovelace, J. W., Wen, T. H., Reinhard, S., Hsu, M. S., Sidhu, H., Ethell, I. M., Binder, D. K., & Razak, K. A. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.02.002 · Cited by 115
Auditory Processing in Fragile X Syndrome
Rotschafer, S. E., & Razak, K. A. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00019 · Cited by 116
Wilkinson, C. L., & Nelson, C. A. (2021) · Molecular Autism · doi:10.1186/s13229-021-00425-x · Cited by 101
Tomé, D., Barbosa, F., Nowak, K., & Teixeira, J. M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1258-3 · Cited by 100
Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
Protic, D. D., Aishworiya, R., Salcedo‐Arellano, M. J., Tang, S. J., Milisavljevic, J., Mitrovic, F., Hagerman, R. J., & Budimirovic, D. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041935 · Cited by 103
Self-citationMultielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome
Jonak, C. R., Lovelace, J. W., Ethell, I. M., Razak, K. A., & Binder, D. K. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104794 · Cited by 87
Developmental studies in fragile X syndrome
Razak, K. A., Dominick, K. C., & Erickson, C. A. (2020) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-020-09310-9 · Cited by 87
Lovelace, J. W., Rais, M., Palacios, A. R., Shuai, X. S., Bishay, S., Popa, O., Pirbhoy, P. S., Binder, D. K., Nelson, D. L., Ethell, I. M., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz141 · Cited by 82
Neural Hyperexcitability in Autism Spectrum Disorders
Takarae, Y., & Sweeney, J. (2017) · Brain Sciences · doi:10.3390/brainsci7100129 · Cited by 82
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 89
Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome
Wen, T. H., Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.047 · Cited by 81
Transient ECM protease activity promotes synaptic plasticity
Magnowska, M., Górkiewicz, T., Beroun, A., Wawrzyniak, M., Rutkowska-Włodarczyk, I., Kaczmarek, L., & Włodarczyk, J. (2016) · Scientific Reports · doi:10.1038/srep27757 · Cited by 75
Brain-wide visual habituation networks in wild type and fmr1 zebrafish
Legorreta, E. M., Constantin, L., Piber, M., Favre‐Bulle, I. A., Taylor, M. A., Blevins, A. S., Giacomotto, J., Bassett, D. S., Vanwalleghem, G. C., & Scott, E. K. (2022) · Nature Communications · doi:10.1038/s41467-022-28299-4 · Cited by 72
Modulation of the GABAergic pathway for the treatment of fragile X syndrome
Hagerman, R. J., Lozano, R., & Hare, E. B. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s42919 · Cited by 70
Self-citationMechanisms underlying auditory processing deficits in Fragile X syndrome
McCullagh, E. A., Rotschafer, S. E., Auerbach, B. D., Klug, A., Kaczmarek, L. K., Cramer, K. S., Kulesza, R. J., Razak, K. A., Lovelace, J. W., Lu, Y., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902435r · Cited by 66
Pirbhoy, P. S., Rais, M., Lovelace, J. W., Woodard, W., Razak, K. A., Binder, D. K., & Ethell, I. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15037 · Cited by 62
van der Molen, M. J. W., Stam, C. J., & van der Molen, M. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088451 · Cited by 61
Local cortical circuit correlates of altered EEG in the mouse model of Fragile X syndrome
Goswami, S., Cavalier, S., Sridhar, V., Huber, K. M., & Gibson, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.002 · Cited by 55
Díaz‐Caneja, C. M., State, M. W., Hagerman, R. J., Jacquemont, S., Marín, Ó., Bagni, C., Umbricht, D., Simonoff, E. A., Andres-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 56
Self-citationNeural Correlates of Auditory Hypersensitivity in Fragile X Syndrome
Razak, K. A., Binder, D. K., & Ethell, I. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.720752 · Cited by 55
Treatment of the psychiatric problems associated with fragile X syndrome
Hagerman, R. J., & Polussa, J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000131 · Cited by 52
Self-citationDevitt, N. M., Gallagher, L., & Reilly, R. B. (2015) · Brain Sciences · doi:10.3390/brainsci5020092 · Cited by 84
Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
Kozono, N., Okamura, A., Honda, S., Matsumoto, M., & Mihara, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-75893-x · Cited by 47
Reusable Multielectrode Array Technique for Electroencephalography in Awake Freely Moving Mice
Jonak, C. R., Lovelace, J. W., Ethell, I. M., Razak, K. A., & Binder, D. K. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00053 · Cited by 42
Best Practices in Fragile X Syndrome Treatment Development
Erickson, C. A., Kaufmann, W. E., Budimirovic, D. B., Lachiewicz, A. M., Haas‐Givler, B., Miller, R. M., Weber, J. D., Abbeduto, L., Hessl, D. R., Hagerman, R. J., et al. (2018) · Brain Sciences · doi:10.3390/brainsci8120224 · Cited by 43
Self-citationEmerging pharmacologic treatment options for fragile X syndrome
Erickson, C. A., Schaefer, T. L., & Davenport, M. H. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s35673 · Cited by 44
Carreño-Muñoz, M. I., Martins, F., Medrano, M., Aloisi, E., Pietropaolo, S., Dechaud, C., Subashi, E., Bony, G., Ginger, M. R., Moujahid, A., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.149 · Cited by 44
The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
Castagnola, S., Bardoni, B., & Maurin, T. (2017) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2017.00015 · Cited by 42
Hyperexcitability and impaired intracortical inhibition in patients with fragile-X syndrome
Morin‐Parent, F., Champigny, C. M., Lacroix, A., Corbin, F., & Lepage, J. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0650-z · Cited by 46
Repurposing available drugs for neurodevelopmental disorders: The fragile X experience
Tranfaglia, M. R., Thibodeaux, C., Mason, D. J., Brown, D., Roberts, I., Smith, R. J., Guilliams, T., & Cogram, P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.004 · Cited by 41
Review of targeted treatments in fragile X syndrome
Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 38
Self-citationMinocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00771 · Cited by 39
EEG as a translational biomarker and outcome measure in fragile X syndrome
Kenny, A., Wright, D., & Stanfield, A. C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01796-2 · Cited by 36
Pharmacotherapy for Fragile X Syndrome: Progress to Date
Davenport, M. H., Schaefer, T. L., Friedmann, K., Fitzpatrick, S. E., & Erickson, C. A. (2016) · Drugs · doi:10.1007/s40265-016-0542-y · Cited by 33
Developmental Emergence of Phenotypes in the Auditory Brainstem Nuclei ofFmr1Knockout Mice
Rotschafer, S. E., & Cramer, K. S. (2017) · eNeuro · doi:10.1523/eneuro.0264-17.2017 · Cited by 30
Toledo, M. A., Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112068 · Cited by 31
Nguyen, A. O., Binder, D. K., Ethell, I. M., & Razak, K. A. (2020) · Journal of Neurophysiology · doi:10.1152/jn.00706.2019 · Cited by 28
Knoth, I. S., Lajnef, T., Rigoulot, S., Lacourse, K., Vannasing, P., Michaud, J. L., Jacquemont, S., Major, P., Jerbi, K., & Lippé, S. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9223-3 · Cited by 31
Kulinich, A. O., Reinhard, S. M., Rais, M., Lovelace, J. W., Scott, V., Binder, D. K., Razak, K. A., & Ethell, I. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104622 · Cited by 30
Kokash, J., Alderson, E. M., Reinhard, S. M., Crawford, C. A., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.029 · Cited by 31
Quantitative EEG Analysis in Angelman Syndrome: Candidate Method for Assessing Therapeutics
Martinez, L. A., Born, H. A., Harris, S., Regnier‐Golanov, A., Grieco, J. C., Weeber, E. J., & Anderson, A. E. (2020) · Clinical EEG and Neuroscience · doi:10.1177/1550059420973095 · Cited by 25
Development of Neural Response to Novel Sounds in Fragile X Syndrome: Potential Biomarkers
Ethridge, L. E., Thaliath, A. P., Kraff, J., Nijhawan, K., & Berry‐Kravis, E. (2020) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-125.6.449 · Cited by 24
State‐of‐the‐art therapies for fragile X syndrome
Protic, D. D., & Hagerman, R. J. (2024) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15885 · Cited by 25
Self-citationSalazar, I. L., Caldeira, M. V., Curcio, M., & Duarte, C. B. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1752-5 · Cited by 26
Functional consequences of postnatal interventions in a mouse model of Fragile X syndrome
Rais, M., Lovelace, J. W., Shuai, X. S., Woodard, W., Bishay, S., Estrada, L., Sharma, A. R., Nguy, A. K., Kulinich, A. O., Pirbhoy, P. S., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105577 · Cited by 25
Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome
Jonak, C. R., Pedapati, E. V., Schmitt, L., Assad, S. A., Sandhu, M. S., DeStefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., et al. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09455-9 · Cited by 23
EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome
Proteau-Lemieux, M., Knoth, I. S., Agbogba, K., Côté, V., Biag, H. M. B., Thurman, A. J., Martin, C.-O., Bélanger, A.-M., Rosenfelt, C. S., Tassone, F., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716707 · Cited by 28
Self-citationPhenotypic analysis of multielectrode array EEG biomarkers in developing and adult male Fmr1 KO mice
Jonak, C. R., Assad, S. A., Garcia, T. A., Sandhu, M. S., Rumschlag, J. A., Razak, K. A., & Binder, D. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106496 · Cited by 23
Genetics, molecular control and clinical relevance of habituation learning
Blok, L. E. R., Boon, M., van Reijmersdal, B., Höffler, K. D., Fencková, M., & Schenck, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104883 · Cited by 23
Jonak, C. R., Sandhu, M. S., Assad, S. A., Barbosa, J. A., Makhija, M. T., & Binder, D. K. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01005-w · Cited by 18
Champigny, C., Morin-Parent, F., Bellehumeur-Lefebvre, L., Çaku, A., Lepage, J.-F., & Corbin, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.762967 · Cited by 16
New Therapeutic Options for Fragile X Syndrome
Jalnapurkar, I. R., Cochran, D., & Frazier, J. A. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0551-8 · Cited by 15
Targeted treatments in fragile X syndrome
Hare, E. B., Hagerman, R. J., & Lozano, R. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.903795 · Cited by 14
Self-citationFragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
Hagerman, R. J., & Hagerman, P. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-090147 · Cited by 12
Self-citationElectrophysiological Biomarkers in Genetic Epilepsies
Armstrong, C., & Marsh, E. D. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01132-4 · Cited by 12
Targeted therapy of cognitive deficits in fragile X syndrome
Puścian, A., Winiarski, M., Borowska, J., Łęski, S., Górkiewicz, T., Chaturvedi, M., Nowicka, K., Wołyniak, M., Chmielewska, J. J., Nikolaev, T., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01527-5 · Cited by 11
Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
Laroui, A., Galarneau, L., Abolghasemi, A., Benachenhou, S., Plantefève, R., Bouchouirab, F. Z., Lepage, J., Corbin, F., & Çaku, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-19476-y · Cited by 10
An, W. W., Nelson, C. A., & Wilkinson, C. L. (2022) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2022.987184 · Cited by 10
Matusiak, M., Oziębło, D., Ołdak, M., Rejmak, E., Kaczmarek, L., Skarzynski, P. H., & Skarżyńśki, H. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02732-7 · Cited by 8
Erickson, C. A., Shaffer, R. C., Will, M., Schmitt, L., Horn, P. S., Hirst, K., Pedapati, E. V., Ober, N., Tumuluru, R. V., Handen, B. L., et al. (2023) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-023-06132-1 · Cited by 9
Studying child development in genetic models of ASD
Garg, S., & Green, J. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.009 · Cited by 8
Hyper-extralemniscal model of Fragile X syndrome
Miyakoshi, M., Kim, H., Stefano, L. A. D., Schmitt, L., Norris, J. E., Ethridge, L. E., Erickson, C. A., & Pedapati, E. V. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf141 · Cited by 6
Auger, E., Berry-Kravis, E. M., & Ethridge, L. E. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109501 · Cited by 6
Astrocytic GABA controls fidelity of temporal cortical processing in Fragile X Syndrome
Wagner, V. A., Thapa, R., Norman, A. O., Varallo, A., Wimberly, J., Rais, M., Gerasymchuk, D., Piepponen, P. T., Razak, K. A., Castrén, M. L., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107233 · Cited by 8
Morin‐Parent, F., Champigny, C. M., Cote, S. R., Mohamad, T., Hasani, S. A., Çaku, A., Corbin, F., & Lepage, J. (2024) · Autism Research · doi:10.1002/aur.3222 · Cited by 5
McKinney, W. S., Schmitt, L., Stefano, L. A. D., Ethridge, L. E., Norris, J. E., Horn, P. S., Dauterman, S., Rosselot, H., Pedapati, E. V., Reisinger, D. L., et al. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0103 · Cited by 5
Fragile X-Associated Disorders
Lozano, R., Hare, E. B., & Hagerman, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00017-6 · Cited by 5
Self-citationOverview of Targeted Double-Blind, Placebo-Controlled Clinical Trials in Fragile X Syndrome
Ligsay, A., Hagerman, R. J., & Berry‐Kravis, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00019-6 · Cited by 4
Self-citationHarkins, C. M., Dominick, K. C., Wink, L. K., Pedapati, E. V., Shaffer, R. C., Fitzpatrick, S. E., Davenport, M. H., Sweeney, J. A., & Erickson, C. A. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0199-1 · Cited by 4
Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Telias, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191102165206 · Cited by 4
Fragile X-Associated Disorders
Summers, S. M., & Hagerman, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00008-2 · Cited by 4
Self-citationStanfield, A. C., & McKechanie, A. G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2510408 · Cited by 3
Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
Scharf, S. H., Gasparini, F., Spooren, W. P. J. M., & Lindemann, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00018-4 · Cited by 3
Rais (2022) · doi:10.1101/2022.02.08.479618 · Cited by 2
Matrix Metalloproteinases in Fragile X Syndrome
Ethell, D. W., & Sidhu, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00015-9 · Cited by 2
Goel, A., Razak, K. A., Chubykin, A. A., & Antoine, M. W. (2025) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-025-09634-4 · Cited by 1
Legorreta, E. M. (2020) · The University of Queensland · doi:10.14264/uql.2020.647
Baclofen-Associated Neurophysiologic Target Engagement Across Species in Fragile X SyndromePreprint
Jonak, C. R., Pedapati, E. V., Schmitt, L., Assad, S. A., Sandhu, M. S., DeStefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-970688/v1
Síndrome X frágil y otras patologías asociadas al gen FMR1
Juárez, J. C. C., de León, M. J. Z., Díaz, D. J. S., Alvarado, C. G. B., García, D. A. S., & Arévalo, G. S. (2021) · Revista Med · doi:10.18359/rmed.5262 · Cited by 1
An, W. W., Nelson, C. A., & Wilkinson, C. L. (2022) · medRxiv · doi:10.1101/2022.07.05.22277114
Steenbergen, A. V., Minhas, A., Lin, T. R., Kaur, M., & Bolduc, F. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3439158/v1
Chojnacka, M., Skupien, A., & Dziembowska, M. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1604262
Associations Between Altered Auditory EEG Markers and Clinical Impairments in Fragile X Syndrome
Proteau-Lemieux, M., Knoth, I. S., Davoudi, S., Martin, C.-O., Bélanger, A.-M., Fontaine, V. K., Biag, H. M. B., Abbeduto, L., Jacquemont, S., Hessl, D. R., et al. (2025) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-025-07076-4 · Cited by 1
Self-citationKassir, M. H., Lovelace, J. W., Binder, D. K., Ethell, I. M., & Razak, K. A. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2564628
Metadata
- Authors
- Schneider, A., Leigh, M. J., Adams, P., Nanakul, R., Chechi, T., Olichney, J., Hagerman, R., & Hessl, D.
- Affiliations
- University of California Davis Medical Center (US)
- University of Washington (US)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-08-27
- Volume
- 27
- Issue
- 10
- Pages
- 956-963
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC4962861
- OpenAlex
- W2006050076
- Cited by
- 108
- References
- 29
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 15 · 2021: 12 · 2020: 10 · 2019: 11 · 2018: 10 · 2017: 13 · 2016: 7 · 2015: 6 · 2014: 8
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Fragile X Foundation
- Centers for Disease Control and Prevention (U50DD000596)
- National Institute on Aging (NIARL1AG032115, RL1AG032115)
- National Center for Research Resources (UL1RR024141, UL1RR024146, KL2RR024141)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fragile X syndrome, minocycline, event-related potentials, auditory oddball paradigm, current source density, N1 and P2 components, cognitive biomarkers, treatment response monitoring, children
- MeSH terms
- Anti-Bacterial Agents, Child, Double-Blind Method, Evoked Potentials, Auditory, Female, Fragile X Syndrome, Habituation, Psychophysiologic, Humans, Male, Minocycline, Cross-Over Studies, Biomarkers, Pharmacological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
